Cerar, A.; Poglajen, G.; Zemljič, G.; Frljak, S.; Žorž, N.; Jaklič, M.; Okrajšek, R.; Šebeštjen, M.; Vrtovec, B.
SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial. Biomedicines 2025, 13, 2773.
https://doi.org/10.3390/biomedicines13112773
AMA Style
Cerar A, Poglajen G, Zemljič G, Frljak S, Žorž N, Jaklič M, Okrajšek R, Šebeštjen M, Vrtovec B.
SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial. Biomedicines. 2025; 13(11):2773.
https://doi.org/10.3390/biomedicines13112773
Chicago/Turabian Style
Cerar, Andraž, Gregor Poglajen, Gregor Zemljič, Sabina Frljak, Neža Žorž, Martina Jaklič, Renata Okrajšek, Miran Šebeštjen, and Bojan Vrtovec.
2025. "SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial" Biomedicines 13, no. 11: 2773.
https://doi.org/10.3390/biomedicines13112773
APA Style
Cerar, A., Poglajen, G., Zemljič, G., Frljak, S., Žorž, N., Jaklič, M., Okrajšek, R., Šebeštjen, M., & Vrtovec, B.
(2025). SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial. Biomedicines, 13(11), 2773.
https://doi.org/10.3390/biomedicines13112773
